Emerging treatments for the primary headache disorders.
作者： Nathaniel M. Schuster , Sarah Vollbracht , Alan M. Rapoport
DOI: 10.1007/S10072-015-2133-1
关键词:
摘要: Migraine and cluster headache are common, episodic, often chronic disabling disorders of the brain. Although there many standard treatment techniques, none ideal. This article reviews various novel pharmacologic device-related treatments for migraine headache. Emphasis is given to recent advances in development monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) its receptor, including promising results from phase 2 trials studying safety efficacy LY2951742, ALD403 TEV-48125, three anti-CGRP mAbs. Other new discussed include 5-HT1F receptor agonist lasmiditan glial cell modulator ibudilast. Also reviewed neuromodulation headache, randomized controlled sphenopalatine ganglion stimulation, trigeminal nerve transcutaneous vagus transcranial magnetic stimulation. Finally, we discuss patch, inhaled, intranasal methods triptan dihydroergotamine delivery.
springer.com
elsevier.com
sci-hub.se 参考文章(17)
Tony W Ho, Kathryn M Connor, Ying Zhang, Eric Pearlman, Janelle Koppenhaver, Xiaoyin Fan, Christopher Lines, Lars Edvinsson, Peter J Goadsby, David Michelson, Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention Neurology. ,vol. 83, pp. 958- 966 ,(2014) , 10.1212/WNL.0000000000000771
PJ Goadsby, BM Grosberg, A Mauskop, R Cady, KA Simmons, Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia. ,vol. 34, pp. 986- 993 ,(2014) , 10.1177/0333102414524494
David W Dodick, Peter J Goadsby, Stephen D Silberstein, Richard B Lipton, Jes Olesen, Messoud Ashina, Kerri Wilks, David Kudrow, Robin Kroll, Bruce Kohrman, Robert Bargar, Joe Hirman, Jeff Smith, Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial Lancet Neurology. ,vol. 13, pp. 1100- 1107 ,(2014) , 10.1016/S1474-4422(14)70209-1
Markus Färkkilä, Hans-Christoph Diener, Gilles Géraud, Miguel Láinez, Jean Schoenen, Nadja Harner, Alison Pilgrim, Uwe Reuter, Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurology. ,vol. 11, pp. 405- 413 ,(2012) , 10.1016/S1474-4422(12)70047-9
J. Schoenen, B. Vandersmissen, S. Jeangette, L. Herroelen, M. Vandenheede, P. Gerard, D. Magis, Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial Neurology. ,vol. 80, pp. 697- 704 ,(2013) , 10.1212/WNL.0B013E3182825055
Joel R Saper, David W Dodick, Stephen D Silberstein, Sally McCarville, Mark Sun, Peter J Goadsby, Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. ,vol. 31, pp. 271- 285 ,(2011) , 10.1177/0333102410381142
Denys Fontaine, Clair Vandersteen, Delphine Magis, Michel Lanteri-Minet, Neuromodulation in cluster headache. Advances and technical standards in neurosurgery. ,vol. 42, pp. 3- 21 ,(2015) , 10.1007/978-3-319-09066-5_1
Sheena K. Aurora, Stephen D. Silberstein, Shashidhar H. Kori, Stewart J. Tepper, Scott W. Borland, Min Wang, David W. Dodick, MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine Headache: The Journal of Head and Face Pain. ,vol. 51, pp. 507- 517 ,(2011) , 10.1111/J.1526-4610.2011.01869.X
Jean Schoenen, Rigmor Højland Jensen, Michel Lantéri-Minet, Miguel JA Láinez, Charly Gaul, Amy M Goodman, Anthony Caparso, Arne May, Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study Cephalalgia. ,vol. 33, pp. 816- 830 ,(2013) , 10.1177/0333102412473667
Roger K. Cady, Peter J. McAllister, Egilius L.H. Spierings, John Messina, Jennifer Carothers, Per G. Djupesland, Ramy A. Mahmoud, A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study) Headache. ,vol. 55, pp. 88- 100 ,(2015) , 10.1111/HEAD.12472